Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMYTNASDAQ:COGTNASDAQ:INVANASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsCOGTCogent Biosciences$7.24-5.0%$5.35$3.72▼$12.61$867.59M1.821.32 million shs3.08 million shsINVAInnoviva$21.46+0.1%$19.25$15.70▼$22.00$1.35B0.37682,932 shs633,760 shsMIRMMirum Pharmaceuticals$50.80+0.2%$43.86$28.56▼$54.23$2.51B0.95493,818 shs414,089 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%COGTCogent Biosciences-4.99%-0.28%+45.38%-0.69%-14.82%INVAInnoviva+0.09%+0.42%+15.19%+24.69%+32.31%MIRMMirum Pharmaceuticals+0.20%+4.83%+13.17%+6.12%+73.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/ACOGTCogent Biosciences1.9818 of 5 stars3.43.00.00.02.00.00.6INVAInnoviva4.1449 of 5 stars3.50.00.04.22.71.71.9MIRMMirum Pharmaceuticals3.691 of 5 stars3.61.00.04.22.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt Pharma 0.00N/AN/AN/ACOGTCogent Biosciences 2.75Moderate Buy$14.57101.26% UpsideINVAInnoviva 3.00Buy$55.00156.29% UpsideMIRMMirum Pharmaceuticals 3.13Buy$65.5028.94% UpsideCurrent Analyst Ratings BreakdownLatest AMYT, COGT, INVA, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/29/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $25.005/20/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.005/7/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AINVAInnoviva$358.71M3.76$3.43 per share6.26$11.03 per share1.95MIRMMirum Pharmaceuticals$336.89M7.47N/AN/A$4.70 per share10.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/ACOGTCogent Biosciences-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A13.85N/A-16.15%15.77%8.41%7/29/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)Latest AMYT, COGT, INVA, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94COGTCogent BiosciencesN/A5.135.13INVAInnoviva0.402.482.30MIRMMirum Pharmaceuticals1.323.223.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%COGTCogent BiosciencesN/AINVAInnoviva99.12%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%COGTCogent Biosciences7.29%INVAInnoviva2.25%MIRMMirum Pharmaceuticals14.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableMIRMMirum Pharmaceuticals14049.53 million42.42 millionOptionableAMYT, COGT, INVA, and MIRM HeadlinesRecent News About These CompaniesLiver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load UpJune 17 at 3:58 PM | msn.comBrokers Set Expectations for MIRM FY2026 EarningsJune 11, 2025 | marketbeat.comAnalysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $60.73June 11, 2025 | americanbankingnews.comMirum Pharmaceuticals Inc.June 11, 2025 | barrons.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 10, 2025 | businesswire.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from AnalystsJune 8, 2025 | marketbeat.comWhy Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?June 6, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.06 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 6, 2025 | marketbeat.comSecure Asset Management LLC Purchases 8,990 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 4, 2025 | marketbeat.comSquarepoint Ops LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 2, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Position Decreased by Two Sigma Investments LPMay 29, 2025 | marketbeat.comMan Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 29, 2025 | marketbeat.comMirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potentialMay 27, 2025 | investing.comVoloridge Investment Management LLC Sells 85,242 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 27, 2025 | marketbeat.comTwo Sigma Advisers LP Trims Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 26, 2025 | marketbeat.comWoodline Partners LP Acquires 73,399 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 24, 2025 | marketbeat.comNuveen Asset Management LLC Has $29.86 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)May 24, 2025 | marketbeat.comEquities Analysts Offer Predictions for MIRM Q2 EarningsMay 23, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Rafferty Asset Management LLCMay 23, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Millennium Management LLCMay 23, 2025 | marketbeat.comMirum Pharmaceuticals at RBC Conference: Strategic Growth HighlightsMay 22, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMYT, COGT, INVA, and MIRM Company DescriptionsAmryt Pharma NASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Cogent Biosciences NASDAQ:COGT$7.24 -0.38 (-4.99%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.49 +0.25 (+3.45%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Innoviva NASDAQ:INVA$21.46 +0.02 (+0.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$21.46 0.00 (0.00%) As of 06/18/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Mirum Pharmaceuticals NASDAQ:MIRM$50.80 +0.10 (+0.20%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$50.77 -0.03 (-0.06%) As of 06/18/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
